Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

Biogen Idec Gains Phase II MS, Cancer Biologics Through PDL Deal

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

The agreement gives Biogen rights to Protein Design Labs' daclizumab, volociximab and fontolizumab.

You may also be interested in...



Ophthotech Will Take Biogen/PDL Drug Volociximab Into The Clinic For AMD

Alpha 5 beta 1 integrin antagonist will move into the clinic “shortly,” CEO Patel tells “The Pink Sheet” DAILY.

Ophthotech Will Take Biogen/PDL Drug Volociximab Into The Clinic For AMD

Alpha 5 beta 1 integrin antagonist will move into the clinic “shortly,” CEO Patel tells “The Pink Sheet” DAILY.

Biogen Idec/PDL BioPharma Plan To Study Daclizumab As Monotherapy For MS

Phase II monotherapy trial for the monoclonal antibody will initiate in the second half of 2007, PDL tells “The Pink Sheet” DAILY.

Table

View full table

Related Content

Pink Sheet
Pink Sheet
Pink Sheet
Pink Sheet
Pink Sheet

Topics

Tags:
BioPharmaceutical
Latest Headlines

WHO Examines Ethical Criteria For Human Challenge Trials Ahead Of Next Health Emergency

Post-Brexit UK Risks Being ‘Left Out In The Cold’ As EU Coordinates Action On Shortages

Gene Therapy: Pediatric Development Could Start Sooner Than Sponsors Think – FDA OTP Director

Puberty Blockers: FDA's Califf Asked If REMS, Boxed Warning Against Off-Label Use In The Works

See All
UsernamePublicRestriction

Register

PS062797

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By